BUZZ-Immunome dips after launching $400 mln stock offering

Reuters12-16
BUZZ-Immunome dips after launching $400 mln stock offering

** Shares of biotech co Immunome IMNM.O fall 2% post-market to $22.19 as it seeks equity

** Bothell, Washington-based IMNM commences $400 mln stock offering

** IMNM shares closed up 15.7% at $22.64 on Mon after co said its experimental drug, varegacestat, met main goal in late-stage study for patients with a rare type of tumor

** Leerink, J.P. Morgan, TD Cowen, Goldman and Guggenheim are joint bookrunners for the offering

** With ~91.7 mln shares outstanding, co has ~$2.1 bln market cap

** Through Mon, shares up 113% YTD

** All 13 analysts rate shares "strong buy" or "buy"; median PT of $32 up from $22 a month ago, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment